Buy tirzepatide peptide Canada dual agonist research Durham Peptides Tirzepatide represents the second generation of incretin peptide research — the first dual-agonist compound to activate both GLP-1 and GIP receptors simultaneously. For Canadian researchers studying metabolic peptide pharmacology, tirzepatide sits at the intersection of single-agonist semaglutide (older generation) and triple-agonist retatrutide (newer generation), making it a central reference compound for